Hepatitis B Virus (HBV) Infection Market

Table of Content

1. INTRODUCTION
   1. Study Assumptions and Market Definition
   2. Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
   1. Market Overview
   2. Market Drivers
      1. Development of Therapeutic Vaccination Technology (TherVacB Caccine)
   3. Market Restraints
      1. Persistent Socioeconomic Disparities
      2. High Doses of Medications Lead to the Complication
   4. Market Opportunities
      1. Development of New Types of Medications with Higher Efficacy
   5. Market Trends
      1. Increasing Emphasis on Combination Therapies
5. MARKET SEGMENTATION
   1. By Type
      1. Acute
      2. Chronic
   2. By Treatment
      1. Immune modulator Drugs
      2. Interferon Alpha (Intron A)
      3. Pegylated Interferon (Pegasys)
      4. Antiviral Drugs
      5. Tenofovir disoproxil (Viread)
      6. Tenofovir alafenamide (Vemlidy)
      7. Entecavir (Baraclude)
      8. Telbivudine (Tyzeka or Sebivo)
      9. Adefovir Dipivoxil (Hepsera)
      10. Lamivudine (Epivir-HBV, Zeffix, or Heptodin)
      11. Others
      12. Vaccines
      13. Combination Vaccine
      14. Single Antigen Vaccine
      15. Surgery
   3. By Distribution Channel
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
   4. By Key Geographic Regions
      1. North America
         1. United States
         2. Canada
         3. Mexico
      2. Europe
         1. Germany
         2. United Kingdom
         3. France
         4. Italy
         5. Spain
         6. Rest of Europe
      3. Asia Pacific
         1. China
         2. Japan
         3. India
         4. Australia
         5. South Korea
         6. Rest of Asia Pacific
      4. Middle East and Africa
         1. GCC
         2. South Africa
         3. Rest of Middle East and Africa
      5. South America
         1. Brazil
         2. Argentina
         3. Rest of South America
6. COMPETITIVE LANDSCAPE
   1. Company Profile
      1. Accord Healthcare Inc.
      2. Apotex Corp.
      3. Arbutus Biopharma
      4. Arrowhead Pharma
      5. Aurobindo Pharma Limited
      6. Bristol-Myers Squibb
      7. Gilead Sciences, Inc.
      8. GlaxoSmithKline
      9. Lupin Pharmaceuticals Inc.
      10. Merck & Co. Inc
7. MARKET OPPORTUNITIES AND FUTURE TRENDS

Frequently Asked Questions

Q.1. What is the projected market value of the global Hepatitis B Virus (HBV) Infectionmarket?

The global market of Hepatitis B Virus (HBV) Infection is projected to reach USD 7.11 Bn by 2033.

Q.2. What is the estimated growth rate (CAGR) of the global Hepatitis B Virus (HBV) Infectionmarket?

The global Hepatitis B Virus (HBV) Infection market has an estimated annual growth rate of 3.8% .

Q.3. What are the recent trends of Hepatitis B Virus (HBV) Infectionmarket?

Increasing emphasis on combination therapiesis one of the major trends of the market that is projected to boost the market growth in the near future.

Q.4. Which are the top companies to hold the market share in Hepatitis B Virus (HBV) Infection?

The major companies profiled in this report include Accord Healthcare Inc., Apotex Corp., Arbutus Biopharma, Arrowhead Pharma, Aurobindo Pharma Limited, Bristol-Myers Squibb, Gilead Sciences, Inc., GlaxoSmithKline, Lupin Pharmaceuticals Inc., Merck & Co. Inc, among others.

Q.5. Which region is estimated to held highest CAGR inHepatitis B Virus (HBV) Infectionmarket?

North America is estimated to hold biggest share in the market for Hepatitis B Virus (HBV) Infection.